CCR5 Delta32 polymorphism: associated with gallbladder cancer susceptibility
A Srivastava1, S N Pandey, G Choudhuri
1Department of Genetics, Sanjay Gandhi Post Graduate Institute of Medical Sciences (SGPGIMS), Lucknow, UP, India.
Scandinavian Journal of Immunology
|April 15, 2008
Summary
The CCR5 Delta32 gene variant increases gallbladder cancer risk, especially in early-onset cases and tobacco users. This genetic susceptibility is independent of gallstones.
Area of Science:
- Genetics
- Oncology
- Immunology
Background:
- Gallbladder inflammation is a known risk factor for gallbladder cancer (GBC).
- Chemokine receptors are involved in immune responses, inflammation, and cancer development.
Purpose of the Study:
- To investigate the association between CCR5 Delta32 polymorphism and genetic susceptibility to GBC.
- To explore how this polymorphism influences GBC risk in relation to factors like gallstones, age of onset, gender, and tobacco use.
Main Methods:
- A case-control study involving 144 GBC patients and 210 healthy controls.
- Genotyping performed using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique.
Main Results:
- A statistically significant difference in CCR5+/Delta32 genotype and CCR5 Delta32 allele distribution was observed between GBC patients and controls.
- The CCR5 Delta32 allele was significantly associated with early-onset GBC (<50 years) and increased risk in tobacco users.
- The association was independent of gallstone presence and showed only marginal gender influence.
Conclusions:
- The CCR5+/Delta32 genotype and CCR5 Delta32 allele represent significant risk factors for GBC.
- This genetic risk is particularly pronounced in individuals with early-onset disease and those who use tobacco.
- CCR5+/Delta32 polymorphism's role in GBC susceptibility is not dependent on gallstone formation.
More Related Videos
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...